News
APRE
5.05
-2.35%
-0.12
Weekly Report: what happened at APRE last week (0429-0503)?
Weekly Report · 2d ago
Press Release: Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. As Chief Medical Officer. New role enhances company's strong leadership team and solidifies commitment to ongoing clinical innovation. Aprea is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality.
Dow Jones · 6d ago
Weekly Report: what happened at APRE last week (0422-0426)?
Weekly Report · 04/29 11:05
Weekly Report: what happened at APRE last week (0415-0419)?
Weekly Report · 04/22 10:56
Weekly Report: what happened at APRE last week (0408-0412)?
Weekly Report · 04/15 10:49
Aprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy Rating
TipRanks · 04/12 15:35
Optimistic Outlook for Aprea Therapeutics’ Oncology Pipeline: A Comprehensive Buy Rating Analysis
TipRanks · 04/11 10:26
Aprea Therapeutics Announces Presentations On Its Next Generation WEE1 Inhibitor, APR-1051, And A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for cyclin E-overexpressing cancers. APR- 1051 has received FDA clearance for a first in human trial. Company also presented four poster presentations at the American Association of Cancer Research Annual Meeting.
Benzinga · 04/10 16:02
Weekly Report: what happened at APRE last week (0401-0405)?
Weekly Report · 04/08 10:53
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Tevogen Bio Holdings stock rose 85.5% to $4.86 during Thursday's pre-market session. Candel Therapeutics (NASDAQ:CADL) shares rose 27.97% and Healthcare Triangle stock rose 23.56% in the same session. Losers Telesis Bio (NASdaq:TBIO) stock fell 11.8% during the session. Q4 earnings came out today.
Benzinga · 04/04 12:09
Aprea Therapeutics files to sell 4.39M shares of common stock for holders
Seeking Alpha · 04/03 20:30
APREA THERAPEUTICS INC FILES FOR SHELF OF UP TO 4.4 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 04/03 20:08
Weekly Report: what happened at APRE last week (0325-0329)?
Weekly Report · 04/01 10:51
Aprea Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Aprea Therapeutics Inc reports results for the quarter ended in December - Earnings Summary. The company reported a quarterly adjusted loss of 92 cents per share. Revenue was $14.00 thousand; analysts expected a loss of 77 cents. Aprea's shares had risen by 29.1% this quarter.
Reuters · 03/28 12:00
Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating
TipRanks · 03/27 20:05
Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)
TipRanks · 03/27 12:20
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 03/27 12:02
Aprea Therapeutics Price Target Raised to $11.00/Share From $9.00 by Wedbush
Dow Jones · 03/27 12:02
Wedbush Maintains Outperform on Aprea Therapeutics, Raises Price Target to $11
Benzinga · 03/27 11:54
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
Aprea Therapeutics reported earnings per share of -92 cents. This was below the analyst estimate for EPS of -77 cents. The company reported revenue of $14,075. This is 87.20% worse than the estimate for revenue of $110,000.
Investorplace · 03/26 17:53
More
Webull provides a variety of real-time APRE stock news. You can receive the latest news about Aprea Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company's advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA double-strand breaks. It has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received United States Food and Drug Administration (FDA) clearance of its IND. It has an early-stage program that is in the lead optimization stage, for an undisclosed DDR target. The Company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute.